ETS factors such as ETV6, ETS1, FLI1 and ERG are essential for sprouting angiogenesis [31, 32, 33], one of the hallmarks of cancer, and we found that the selected compounds could efficiently inhibit this process, raising the possibility that ETS inhibition might ultimately represent a kill‐two‐birds‐with‐one‐stone approach to tumour targeting. The gene discussed is ETS1; the disease is cancer.